MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
Arbutus Biopharma Corporation Total Non Current Liabilities 2011-2026 | ABUS
Annual Total Non Current Liabilities Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 25.6 M | 25 M | 16.4 M | 40.1 M | 62.3 M | 154 M | 9.94 M | - | 723 K | 1.66 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | 723 K | 37.3 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
2.6 M | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
5.36 M | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
63.6 M | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
2.41 B | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
7.22 B | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
149 M | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
11.5 M | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 101.57 | - | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Immuron Limited
IMRN
|
175 K | $ 0.81 | 0.3 % | $ 9.47 M |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
315 M | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
338 K | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
126 K | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
377 M | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
105 M | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Jaguar Health
JAGX
|
10.3 M | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
5.05 M | $ 26.67 | - | $ 1.44 B | Britain |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Kamada Ltd.
KMDA
|
7.06 M | $ 8.11 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.98 | - | $ 4.91 M | Israel |
 |
Krystal Biotech
KRYS
|
2.78 M | $ 259.95 | - | $ 7.52 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
11.6 M | $ 12.42 | - | $ 1.65 B | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
711 M | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Liquidia Corporation
LQDA
|
10.3 M | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |